Ascendis Pharma A (ASND) Income from Continuing Operations (2014 - 2026)
Ascendis Pharma A (ASND) posted Income from Continuing Operations of 849601923.04 for Q1 2026, down 3577.3% sequentially from 23103935.68 in Q4 2025, and down 773.15% YoY from 126213590.15 in Q1 2025.
Powered by 
Analysis
Ascendis Pharma A (ASND) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Income from Continuing Operations for 13 years, with the latest figure at 849601923.04 in Q1 2026.
- Quarterly Income from Continuing Operations fell 773.15% year-over-year to 849601923.04 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 970819147.07 (down 169.6% YoY) and the FY2025 annual result came in at 293738232.63, up 25.38% from the prior year.
- Income from Continuing Operations eased to 849601923.04 in Q1 2026 per ASND's latest filing, from 23103935.68 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 23103935.68 in Q4 2025 and troughed at 849601923.04 in Q1 2026.
- A 5-year average of 151448336.1 and a median of 116264385.89 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations soared 69.93% in 2025, then tumbled 773.15% in 2026.
- Over 5 years, Income from Continuing Operations stood at 200706122.44 in 2022, then soared by 59.64% to 81013971.39 in 2023, then surged by 52.12% to 38788944.43 in 2024, then surged by 40.44% to 23103935.68 in 2025, then plunged by 3577.3% to 849601923.04 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 849601923.04, 23103935.68, and 62842556.44 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ascendis Pharma A | 16.40 Bn | 15.46 Bn | 362.22 Mn | 294.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 294.33 Mn |
| Mar 31, 2026 | -849.60 Mn |
| Dec 31, 2025 | -23.10 Mn |
| Sep 30, 2025 | -62.84 Mn |
| Jun 30, 2025 | -35.27 Mn |
| Mar 31, 2025 | -97.30 Mn |
| Dec 31, 2024 | -38.79 Mn |
| Sep 30, 2024 | -106.70 Mn |
| Jun 30, 2024 | -117.30 Mn |
| Mar 31, 2024 | -142.35 Mn |
| Dec 31, 2023 | -81.01 Mn |
| Sep 30, 2023 | -175.19 Mn |
| Jun 30, 2023 | -133.17 Mn |
| Mar 31, 2023 | -116.26 Mn |
| Dec 31, 2022 | -200.71 Mn |
| Sep 30, 2022 | -170.69 Mn |
| Jun 30, 2022 | -86.87 Mn |
| Mar 31, 2022 | -140.85 Mn |
| Dec 31, 2021 | -121.33 Mn |
| Sep 30, 2021 | -94.74 Mn |